Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis

被引:10
作者
Guarneri, Valentina [1 ]
Barbieri, Elena [1 ]
Piacentini, Federico [1 ]
Giovannelli, Simona [1 ]
Ficarra, Guido [2 ]
Frassoldati, Antonio [1 ]
Maiorana, Antonino [2 ]
D'Amico, Roberto [1 ]
Conte, PierFranco [1 ]
机构
[1] Modena Univ Hosp, Dept Oncol Hematol & Resp Dis, I-41100 Modena, Italy
[2] Modena Univ Hosp, Dept Pathol, I-41100 Modena, Italy
关键词
Breast cancer; Primary systemic therapy; Neoadjuvant chemotherapy; p53; Ki-67; Tumor biomarkers; Predictive factors; Prognostic factors; SURGICAL ADJUVANT BREAST; NEOADJUVANT CHEMOTHERAPY; COMPLETE RESPONSE; SYSTEMIC THERAPY; APOPTOSIS; EXPRESSION; EFFICACY; DOXORUBICIN; PACLITAXEL; MUTATIONS;
D O I
10.1177/172460081002500208
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction and aims: The p53 protein is a mediator of the cellular response to DNA damage. The aim of this study was to evaluate the predictive and/or prognostic value of p53 expression in relation to the molecular subtypes of breast cancer in patients treated with preoperative chemotherapy. Patients and methods: Patients with stage II-III breast cancer were included in the study. The expression of p53 was evaluated by immunohistochemistry on the diagnostic core biopsy specimen. Patients received 4-6 courses of preoperative chemotherapy. Pathological complete response (pCR) was defined as complete disappearance of invasive tumor in the breast and axillary lymph nodes. Results: 154 patients were included in the study and the molecular subtypes of their tumors were classified as follows: triple negative 18.2%, hormone receptor positive 60.4%, and HER2 positive 21.4%. p53 was expressed in 43.5% of the patients. A significant association between p53 expression and breast cancer molecular subtypes, tumor differentiation, and proliferation was observed. pCR was achieved in 8 patients (5.2%). p53 expression, molecular subtype, and nuclear grading were significant predictors of pCR (odds ratio for pCR in patients with p53-expressing tumors 10.03, p = 0.0077). In univariate analysis, the expression of p53 as well as high proliferation and lymph node involvement after preoperative chemotherapy were predictors of a worse disease-free survival. Patients with p53 positivity also had a worse overall survival. In multivariate analysis, both p53 expression and nodal status after preoperative chemotherapy were significantly associated with disease-free and overall survival: the hazard ratios for relapse and death in patients with p53-expressing versus non-p53-expressing tumors were 2.29 (p = 0.015) and 7.74 (p = 0.002), respectively. The hazard ratios for relapse and death in node-positive versus node-negative patients were 3.63 (p = 0.003) and 3.64 (p = 0.041), respectively. Conclusions: In this series of patients, p53 expression was significantly associated with markers of aggressive tumor biology, and with a higher likelihood of attaining pCR. p53 expression was a negative prognostic parameter for disease-free and overall survival in univariate and multivariate analysis.
引用
收藏
页码:104 / 111
页数:8
相关论文
共 41 条
[41]   American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J].
Wolff, Antonio C. ;
Hammond, M. Elizabeth H. ;
Schwartz, Jared N. ;
Hagerty, Karen L. ;
Allred, D. Craig ;
Cote, Richard J. ;
Dowsett, Mitchell ;
Fitzgibbons, Patrick L. ;
Hanna, Wedad M. ;
Langer, Amy ;
McShane, Lisa M. ;
Paik, Soonmyung ;
Pegram, Mark D. ;
Perez, Edith A. ;
Press, Michael F. ;
Rhodes, Anthony ;
Sturgeon, Catharine ;
Taube, Sheila E. ;
Tubbs, Raymond ;
Vance, Gail H. ;
de Vijver, Marc Van ;
Wheeler, Thomas M. ;
Hayes, Daniel F. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :118-145